Advertisement

New drugs for the treatment of ventricular tachycardia

  • F. Zannad
  • E. Aliot
  • K. Khalife
  • J. M. Gilgenkrantz
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 71)

Abstract

There is a manifest need for more effective and better tolerated therapy in patients with ventricular tachycardia (VT). Electrical and surgical treatments of VT remain to be used in very special circumstances (see elsewhere in this book) and cannot be employed as a large scale preventive therapy. At the moment, they are only indicated in the case of failure of drug therapy.

Keywords

Ventricular Tachycardia Ventricular Arrhythmia Conduction Disturbance Term Efficacy Ventricular Ectopic Beat 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lombardi F, Stein J, Podrid PJ, Graboys TB, Lown B. 1986. Daily reproducibility of electrophysiologic test results in malignant ventricular arrhythmia. Am J Cardiol 57: 96–101.PubMedCrossRefGoogle Scholar
  2. 2.
    Ward DE, Cheesman M, Dancy M. 1986. Effect of intravenous and oral flecainide on ventricular tachycardia. Int J Cardiol 10: 1–12.CrossRefGoogle Scholar
  3. 3.
    Reid PR, Griffith LSC, Platia EV, Ord SE. 1984. Evaluation of flecainide acetate in the management of patients at high risk of sudden cardiac death. Am J Cardiol 53:108B-111B.PubMedCrossRefGoogle Scholar
  4. 4.
    Anderson JL, Lutz JR, Allison SB. 1983. Electrophysiologic and antiarrhythmic effects of oral flecainide in patients with inducible ventricular tachycardia. J Am Coll Cardiol 2:105–114.PubMedCrossRefGoogle Scholar
  5. 5.
    Anderson JL. 1984. Experience with electrophysiologically guided therapy of ventricular tachycardia with flecainide: summary of long-term follow-up. Am J Cardiol 53: 79B-86B.PubMedCrossRefGoogle Scholar
  6. 6.
    Lai R, Chapman PD, Naccarrellig V, Troup PJ, Rinkenberger RL, Dougherty AH, Ruffy R. 1985. Short – and long-term experience with flecainide acetate in the management of refractory life-threatening ventricular arrhythmias. J Am Coll Cardiol 6: 772–779.CrossRefGoogle Scholar
  7. 7.
    Platia E, Estes M, Heine DL, Griffith SC, Garan H, Ruskin J, Reid PR. 1985. Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. Am J Cardiol 55: 956–962.PubMedCrossRefGoogle Scholar
  8. 8.
    Stern H, Scheininger M, Theisen F, Theisen K. 1985. Antiarrhythmic therapy with flecainide in combination and comparison with propranolol. Drugs 29 (suppl. 4): 77–85.PubMedCrossRefGoogle Scholar
  9. 9.
    Flecainide-Quinidine research group. 1983. Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial. Circulation 67: 1117–1123.CrossRefGoogle Scholar
  10. 10.
    Kjeskus J, Bathen J, Orning O, Storstein L. 1984. A double-blind crossover comparison of flecainide acetate and disopyramide phosphate in the treatment of ventricular premature complexes. Am J Cardiol 53: 72B-78B.CrossRefGoogle Scholar
  11. 11.
    Morganroth J, Horowitz LN. 1984. Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 53: 89B-94B.PubMedCrossRefGoogle Scholar
  12. 12.
    Sellers TD, Di Marco JP. 1985. Sinusoidal ventricular tachycardia associated with flecainide acetate. Chest 5: 647–649.Google Scholar
  13. 13.
    Josephson MA, Ikeda N, Singh B. 1984. Effect of flecainide on ventricular function: clinical and experimental correlation. Am J Cardiol 53: 95B-100B.PubMedCrossRefGoogle Scholar
  14. 14.
    Podri DPJ, Schoenberger A, Lown B. 1980. Congestive heart failure caused by oral disopyramide. N Engl J Med 302: 189–192.CrossRefGoogle Scholar
  15. 15.
    Warnowicz MA, Denes P. 1980. Chronic ventricular arrhythmias: comparative drug effectiveness and toxicity. Prog Cardiovasc Dis 23: 225–236.PubMedCrossRefGoogle Scholar
  16. 16.
    Shen EN, Sung RJ, Morady F, Schwartz AB, Scheinman MM, Dicarlo L, Shapiro W. 1984. Electrophysiologic and hemodynamic effects of intravenous propafenone in patints with recurrent ventricular tachycardia. J Am Coll Cardiol 3: 1291–1297.PubMedCrossRefGoogle Scholar
  17. 17.
    Doherty JH, Waxman HL, Kienzle MG, Cassidy DM, Marchlinski FE, Bruxton AE, Josephson ME. 1984. Limited role of intravenous propafenone hydrochloride in the treatment of sustained ventricular tachycardia: electrophysiologic effects and results of programmed ventricular stimulation. J Am Coll Cardiol 4: 378–381.PubMedCrossRefGoogle Scholar
  18. 18.
    Chilson DA, Heger JJ, Zipes DP, Browne KF, Prystowsky EN. 1985. Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia. J Am Coll Cardiol 5: 1407–1413.PubMedCrossRefGoogle Scholar
  19. 19.
    Prystowsky EN, Heger JJ, Chilson DD, Miles WM, Hubbard J, Zipes DP. 1984. Antiarrhythmic and electrophysiologic effects of oral propafenone. Am J Cardiol 54: 26D-28D.PubMedCrossRefGoogle Scholar
  20. 20.
    Heger JJ, Hubbard J, Zipes D, Miles WM, Prystowsky EN. 1986. Propafenone treatment of recurrent ventricular tachycardia: comparison of continuous electrocardiographic recording and electrophysiologic study in predicting drug efficacy. Am J Cardiol 54: 40D-44D.CrossRefGoogle Scholar
  21. 21.
    Palmieri M, Capucci A, Lombardi G, Naccarella F, Bomba E, Bracchetti D. 1984. Studio comparativo sull’eficacia della disopiramide e del propafenone nella prevenzione delle recidive di tachicardia ventricolare. G Ital Cardiol 14: 52–54.Google Scholar
  22. 22.
    Naccarella F, Bracchetti D, Palmieri M, Cantelli I, Bertaccini P, Ambrosioni E. 1985. Comparison of propafenone and disopyramide for treatment of chronic ventricular arrhythmias: placebo – controlled, doubleblind, randomized crossover study. Am Heart J 109: 833–840.PubMedCrossRefGoogle Scholar
  23. 23.
    Rehnqvist N, Ericsson CG, Eriksson S, Olsson G, Svensson G. 1984. Comparative investigation of the antiarrhythmic effect of propafenone (Rythmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. Acta Med Scand 216: 525–530.PubMedCrossRefGoogle Scholar
  24. 24.
    Brodsky MA, Allen BJ, Abate D, Henry WL. 1985. Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure. Am Heart J 110: 794–799.PubMedCrossRefGoogle Scholar
  25. 25.
    Podrid PJ, Cytryn R, Lown B. 1984. Propafenone: non invasive evaluation of efficacy. Am J Cardiol 54: 53D-59D.PubMedCrossRefGoogle Scholar
  26. 26.
    Dinh H, Murphy ML, Baker BJ, De Soyza N, Franciosa JA. 1985. Efficacy of propafenone compared with quinidine in chronic ventricular arrhythmias. Am J Cardiol 55: 1520–1524.PubMedCrossRefGoogle Scholar
  27. 27.
    Podrid PJ, Lown B. 1984. Propafenone: a new agent for ventricular arrhythmia. J Am Coll Cardiol 4: 117–125.PubMedCrossRefGoogle Scholar
  28. 28.
    Di Bianco R, Fletcher RD, Cohen AI, Gottdiener JS, Singh SN, Katz RJ, Bates HR, Sauberbrunn B. 1982. Treatment of frequent ventricular arrhythmia with encainide: assessment using serial ambulatory electrocardiograms intracardiac electrophysiology studies, treadmill exercise tests and radionuclide cineangiographic studies. Circulation 65:1134–1147.CrossRefGoogle Scholar
  29. 29.
    Morganroth J Poul P, iller R, Hsu PH, Lee I, Clark DM for the Encainide research group. 1986. Dose-response range of encainide for benign and potentially lethal ventricular arrhythmias. Am J Cardiol 57: 769–774.PubMedCrossRefGoogle Scholar
  30. 30.
    Anderson JL, Stewart JR, Johnson TA, Lutz JR, Pitt B. 1982. Response to encainide of refractory ventricular tachycardia: clinical application of assays for parent drug and metabolites. J Cardiovasc Pharmacol 4: 812–819.PubMedCrossRefGoogle Scholar
  31. 31.
    Chesnie B, Podrid P, Lown B, Reader E. 1983. Encainide for refractory ventricular tachyarrhythmia. Am J Cardiol52: 495–500.CrossRefGoogle Scholar
  32. 32.
    Duff HJ, Roden DM, Garey EL, Wang T, Primm K, Woosley RL. 1985. Spectrum of antiarrhythmic response to encainide. Am J Cardiol 56: 887–891.PubMedCrossRefGoogle Scholar
  33. 33.
    Winkle RA, Peters F, Kates RE, Tucker C, Harrison DC. 1981. Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. Circulation 64: 290–296.PubMedCrossRefGoogle Scholar
  34. 34.
    Winkle RA, Mason JW, Griffin JC, Ross D. 1981. Malignant ventricular arrhythmias associated with the use of encainide. Am Heart J 102: 857–864.PubMedCrossRefGoogle Scholar
  35. 35.
    Cocco G, Strozzi C, Pansini R, Rochat N, Bulgarelli L, Padvla A, Sfirsi C, Kamal AL, Yassini A. 1984. Antiarrhythmic use of cibenzoline, a new class I antiarrhythmic agent with class 3 and 4 properties in patients with recurrent ventricular tachycardia. Eur Heart J 5:108.PubMedGoogle Scholar
  36. 36.
    Browne KF, Prystowsky EN, Zipes DP, Chilson DA, Heger JJ. 1984. Clinical efficacy and electrophysiologic effects of Cibenzoline therapy in patients with ventricular arrhythmias. J Am Coll Cardiol 3: 857–864.PubMedCrossRefGoogle Scholar
  37. 37.
    Miura DS, Keren G, Torres V, Butler B, Aogaichi K, Somberg JC. 1985. Antiarrhythmic effects of Cibenzoline. Am Heart J 109: 827–833.PubMedCrossRefGoogle Scholar
  38. 38.
    Wasty N, Saksena S, Barr MJ. 1985. Comparative efficacy and safety of oral Cibenzolne and quinidine in ventricular arrhythmias: a randomized crossover study. Am Heart J 110:1181–1188.PubMedCrossRefGoogle Scholar
  39. 39.
    Rigaud M, Jouret G, Canal M, Bardet J, Flouvat B, Bourdarias JP. 1985. Hemodynamic effects of a new antiarrhythmic agent: Cibenzoline. J Pharmacol (Paris) 16: 247–257.Google Scholar
  40. 40.
    Cassagneau B, Calazel J, Puel J, Mashbuau P, Tournadre P, Fauvel J M, Bounhoure J P, Marin T, Narula O S. 1984. Intérêt des tests de provocation dans l’appréciation du traitement des tachycardies ventriculaires par l’amiodarone. Arch Mal Coeur 77: 766–772.PubMedGoogle Scholar
  41. 41.
    Flaker GC, Alpert MA, Webel RR, Ruder MA, Sanfelipo JF, Tsvtakawa RK. 1985. Amiodarone and sustained ventricular arrhythmias: statistical evidence of drug effeciveness. Am Heart J110: 371–375.CrossRefGoogle Scholar
  42. 42.
    Hariman RJ, Gomes JAC, Kang PS, El-Sherif N. 1984. Effects of intravenous amiodarone in patients with inducible repetitive ventricular response and ventricular tachycardia. Am Heart J 107:1109–1117.PubMedCrossRefGoogle Scholar
  43. 43.
    Heger JJ, Prystowsky EN, Zipes DP. 1983. Clinical efficacy of amiodarone in treatment of recurrent ventricular tachycardia and ventricular fibrillation. Am Heart J 106: 887–894.PubMedCrossRefGoogle Scholar
  44. 44.
    Horowitz LN, Greenspan AM, Spielman SR, Webb CR, Morganroth J, Rotmensch H, Sokoloff NM, Rae AP, Segal BL, Kay HR. 1985. Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease. Am J Cardiol 55: 367–371.PubMedCrossRefGoogle Scholar
  45. 45.
    Kaski JC, Girotti LA, Messuti H, Rutitzky B, Rosenbaum MB. 1981. Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone. Circulation 64:273–279.PubMedCrossRefGoogle Scholar
  46. 46.
    Mc Govern, Garan H, Malakoff RF, Dimarco JP, Grant G, Sellers D, Ruskin JN. 1984. Long term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone. Am J Cardiol 53: 1558–1563.PubMedCrossRefGoogle Scholar
  47. 47.
    Nademanee K, Hendrickson JA, Cannom DS, Goldreyer BN, Singh BN. 1981. Control of refractory life-threatening ventricular tachyarrhythmias by amiodarone. Am Heart J 101: 759–768.PubMedCrossRefGoogle Scholar
  48. 48.
    Nademanee K, Hendrickson J, Kannan R, Singh BN. 1982. Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachycardia. Am Heart J 103: 950–953.PubMedCrossRefGoogle Scholar
  49. 49.
    Leak D. 1986. Intravenous amiodarone in the treatment of refractory lifethreatening cardiac arrhythmias in the critically ill patient. Am Heart J 111: 456–462.PubMedCrossRefGoogle Scholar
  50. 50.
    Rasmussen K, Winkle R, Ross D, Griffin J, Peters F, Mason J. 1982. Antiarrhythmic efficacy of amiodarone in recurrent ventricular tachycardia evaluated by multiple electrophysiological and ambulatory ECG recordings. Acta Med Scand 212: 367–374.PubMedCrossRefGoogle Scholar
  51. 51.
    Jaksena S, Rothbart ST, Shah Y, Cappello G. 1984. Clinical efficacy and electropharmacology of continuous intravenous amiodarone infusion and chronic oral amiodarone in refractory ventricular tachycardia. Am J Cardiol 54: 347–352.CrossRefGoogle Scholar
  52. 52.
    Veltri EP, Reid PR, Platia EV, Griffith L. 1985. Results of late programmed electrical stimulation and long-term electrophysiologic effects of amiodarone therapy in patients with refractory ventricular tachycardia. Am J Cardiol 55: 375–379.PubMedCrossRefGoogle Scholar
  53. 53.
    Veltri EP, Reid PR, Platia EV, Griffith LS. 1985. Amiodarone in the treatment of life-threatening ventricular tachycardia: role of Holter monitoring in predicting long-term clinical efficacy. J Am Coll Cardiol 6: 806–813.PubMedCrossRefGoogle Scholar
  54. 54.
    Mc Kenna W, Oakley CM, Krikler DM, Goodwin JF. 1985. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 53: 412–416.Google Scholar
  55. 55.
    Dicarlo LA, Morady F, Sauve MJ, Malone P, Davis JC, Evans-Becc T, Winston SA, Scheinman MM. 1985. Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: risk stratification based on clinical variables. Am J Cardiol 55: 372–374.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Dordrecht 1987

Authors and Affiliations

  • F. Zannad
    • 1
  • E. Aliot
    • 1
  • K. Khalife
    • 1
  • J. M. Gilgenkrantz
    • 1
  1. 1.Département de CardiologieC.H.R.U. de NancyNancy CedexFrance

Personalised recommendations